Braingaze creates next-generation eye-tracking software
The new spin-off of the University of Barcelona and ICREA has patented a system to optimize diagnosis of attention and visual perception problems, like ADHD.
By Biocat
Eye tracking has awoken great interest in recent years in various fields, including health, and has led to many applications to study it. Spin-off Braingaze, created in 2012 by two entrepreneurs from the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA), has developed software to optimize diagnosis of problems related to attention and perception, including attention deficit hyperactive disorder (ADHD).
According to Braingaze founders Hans Supèr and Laszlo Bax, there are currently various devices of this type but “no others can identify what attracts the attention of the person watching.” The biomarker they have patented is non-invasive, precise, fast (in minutes) and can be integrated into existing eye-tracking devices. All of this makes it suitable for newborns, children and adults. Two of the organizations collaborating on the project are Hospital Sant Joan de Déu and the Maresme Healthcare Consortium.
Hans Supèr is an ICREA research fellow in the Psychology Department and head of the UB research group Vision and Control of Action (VISCA) and Laszlo Bax is the founding partner of Bax & Willems Consulting Venturing. For the past two years, the Bosch i Gimpera Foundation has guided the entrepreneurs in establishing their business plan, evaluating their patentability strategy and negotiating technology-transfer contracts.
The UB has joined the Braingaze equity holders, thorough the company Innovative and Scientific Culture (CIC-UB), as they did previously with Enantia, Genmedica Therapeutics, Biocontrol Technologies, Neurotech Pharma, ImmunNovative Developments, Iproteos, Advanced Nanotechnologies, Smalle Technologies, Dapcom-Data Services and Endoasic Technologies.